20-F: Clearmind Medicine Advances Psychedelic Therapies Amidst Financial Challenges

Clearmind Medicine Inc. reports progress in its Phase I/IIa clinical trial for CMND-100 in Alcohol Use Disorder, despite ongoing significant net losses and a going concern warning.

Summary

• Clearmind Medicine Inc. is a clinical-stage pharmaceutical company focused on developing novel psychedelic medicines for mental health disorders, including Alcohol Use Disorder (AUD), binge drinking, eating disorders, obesity, and metabolic disorders.
• The company's flagship treatment, CMND-100 (based on MEAI), is currently in Phase I/IIa clinical trials for AUD in Israel and the United States.
• A Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the Phase I/IIa clinical trial for CMND-100 in November 2025, following a positive interim safety review that reported no serious adverse events, good tolerability, and strong treatment observance.
• Clearmind has incurred significant operating losses since its inception, with net losses of $3,856,983 in 2025, $5,254,678 in 2024, and $8,620,837 in 2023, leading to an accumulated deficit of $27,879,724 as of October 31, 2025.
• The company's financial statements include an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern, necessitating additional financing.
• Research and development expenses increased by 48.7% to $2,056,525 in 2025, primarily due to costs for preclinical programs ahead of clinical trials.
• The company maintains an extensive intellectual property portfolio with nineteen utility patent families, including 32 granted patents and 80 pending applications, covering various compounds and uses.
• Multiple capital raises occurred in 2023, 2024, and 2025 through public offerings and convertible loans, with further offerings in November and December 2025, generating significant gross proceeds.
• Clearmind has entered into several license agreements with Yissum Research Development Company of the Hebrew University of Jerusalem and BIRAD, the R&D company of Bar-Ilan University, for exclusive, worldwide, and sublicensable rights to joint patents for various therapeutic areas.

Sentiment

Score: 4

Explanation: While there is positive clinical trial progress and an expanding IP portfolio, the company's severe financial distress, including substantial accumulated losses, negative operating cash flow, and a 'going concern' warning, significantly overshadows operational achievements. The continuous need for capital raises and the early stage of development for all product candidates indicate high risk and uncertainty.

Positives

• The Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the Phase I/IIa clinical trial for CMND-100, citing no serious adverse events, good tolerability, and strong treatment observance.
• CMND-100 (MEAI) is a non-hallucinogenic neuroplastogen molecule, which could offer a unique and potentially less controversial treatment approach for mental health disorders.
• Preclinical studies for MEAI have shown promising results in reducing alcohol consumption in mice and positive metabolic changes in obesity models, suggesting broad therapeutic potential.
• The company possesses a robust and expanding intellectual property portfolio, including 32 granted patents and 80 pending applications across various therapeutic areas and compound uses.
• MEAI's mechanism of action involves serotonergic and adrenergic receptors, with studies suggesting its role in reducing alcohol intake and controlling craving behaviors.
• The company is actively pursuing multiple indications beyond AUD, including obesity, metabolic disorders, depression, anxiety, and cocaine addiction, diversifying its pipeline.
• Collaboration with SciSparc Ltd. has resulted in the filing of nine joint patent applications, indicating synergistic research efforts.

Negatives

• The company has incurred significant operating losses since its inception, with an accumulated deficit of $27,879,724 as of October 31, 2025.
• The financial statements contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The company has never generated any revenue from product sales and does not anticipate doing so for at least the next several years.
• Net cash used in operating activities was $4,734,498 for the year ended October 31, 2025, indicating continued cash burn.
• The company is highly reliant on additional financing, which may not be available on acceptable terms or at all, posing a risk to its operations and development plans.
• The exercise prices of warrants from previous offerings (April 2023, September 2023, January 2024) were significantly adjusted downwards multiple times, indicating potential dilution and pressure on share price.
• The Israeli study site (IMCA) for the CM-CMND-001 clinical trial was concluded in July 2025 due to financial considerations, which could impact trial timelines or costs.

Risks

• Incurring significant losses for the foreseeable future and potentially never achieving or maintaining profitability.
• Substantial doubt about the ability to continue as a going concern, which could prevent obtaining new financing.
• Inability to successfully complete development, obtain regulatory approvals, and commercialize product candidates.
• Delays or failures in clinical and preclinical development, which are uncertain, lengthy, and expensive processes.
• Product candidates containing psychedelic substances may be subject to evolving controlled substance laws and regulations, potentially delaying or preventing commercialization.
• Public controversy or adverse publicity regarding psychedelic substances could negatively influence the success and market acceptance of therapies.
• Clinical trials may fail to demonstrate substantial evidence of safety and effectiveness, leading to delays or limitations in regulatory approval.
• Results of early-stage clinical trials and preclinical studies may not be predictive of future results in later-stage trials.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Use of product candidates could be associated with unexpected side effects, adverse events, or safety risks, potentially halting development or limiting commercial potential.
• Failure to achieve market acceptance by physicians, patients, and third-party payors, even if regulatory approval is obtained.
• Inability to establish sales and marketing capabilities or enter into effective third-party agreements for commercialization.
• Uncertainty regarding third-party payor coverage and reimbursement status for newly approved products, potentially harming business.
• Failure to comply with healthcare laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA) could lead to substantial penalties.
• Potential classification as a passive foreign investment company (PFIC) could result in adverse U.S. federal income tax consequences for U.S. shareholders.
• Significant competition from major pharmaceutical, biotechnology, and specialty pharmaceutical companies, as well as academic institutions.
• Inability to obtain and maintain effective patent rights or protect trade secrets, which could impair competitive position.
• Exposure to business, regulatory, political, operational, financial, and economic risks associated with international operations, particularly in Israel due to ongoing security concerns.
• Potential for employees and independent contractors to engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Need to expand the organization and potential difficulties in managing this growth, which could disrupt operations.
• Sales of a significant number of common shares or significant short sales could depress the market price and impair ability to raise capital.

Future Outlook

The company anticipates continued significant losses as it advances product candidates through clinical trials and regulatory approvals. Future funding requirements are substantial and depend on the progress and costs of R&D, regulatory review, and commercialization efforts. The company expects to rely on additional financing through equity or debt or out-licensing to meet its objectives. It aims to develop and provide new treatments for mental health disorders, including AUD, binge drinking, eating disorders, obesity, and metabolic disorders, seeing neuroplastogen-based therapies as the future. The company also plans to explore additional innovative molecules and potentially expand internationally.

Management Comments

• "Our goal is to develop and provide new type of treatments for mental health disorders, including AUD, binge drinking and eating disorders, where there is significant unmet need and lack of innovation."
• "We see neuroplastogens based therapies, which previously may have been overlooked or underused, as the future of treatment for a variety of indications."
• "We believe that our solution for AUD can help solve one of the worlds biggest health problems, which costs the United States alone roughly $250 billion each year."
• "Although MEAI remains in development and is not cleared or approved by the FDA or similar foreign regulatory bodies, we believe that our drug candidate has the potential to change the lives of millions who struggle to drink in moderation."
• "We believe that MEAI holds the potential to break the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural pathways such as 5-HT1A that lead to sensible behavior."
• "As we continue to grow our Company, our goal is to continue to invest, develop and produce solutions to help patients that suffer from mental health disorders. We strive to get millions of people out of the cycle of addiction, anxiety, and depression. Not only do we aim to uplift those that are struggling but also their families, communities, and societies."

Industry Context

The company operates in the rapidly evolving psychedelic pharmaceutical industry, which is gaining increasing validation for treating mental health disorders. This industry is characterized by new approaches and technologies, with a focus on neuroplastogen-based therapies. While many competitors are targeting various mental illnesses, Clearmind Medicine Inc. emphasizes its focus on underserved areas like Alcohol Use Disorder (AUD), obesity, and metabolic disorders, where there is a significant unmet need and limited innovation from traditional pharmaceutical agents. The industry is seeing increased acceptance of novel psychedelic approaches, as evidenced by FDA approvals for esketamine and breakthrough therapy designations for psilocybin and MDMA-assisted therapy for PTSD. The company aims to capitalize on this trend by developing non-hallucinogenic compounds that offer a potentially less controversial treatment path. The market opportunity is substantial, with AUD alone costing the U.S. economy billions annually, and mental health inequities imposing a rising economic burden.

Comparison to Industry Standards

• The company's CMND-100 (MEAI) is a neuroplastogen, a class of compounds gaining attention for their potential to induce neuronal plasticity without hallucinogenic effects, differentiating it from traditional psychedelics like psilocybin or LSD.
• While the psychedelic industry is increasingly focusing on mental illnesses, Clearmind Medicine Inc. specifically targets Alcohol Use Disorder (AUD), obesity, and metabolic disorders, which it believes are underserved by most psychedelic companies.
• Current FDA-approved treatments for AUD (disulfiram, naltrexone, acamprosate) have limitations such as high relapse rates and inconvenient regimens, suggesting an unmet need that Clearmind's MEAI aims to address.
• The company faces competition from psychedelic companies focusing on alcohol abuse, such as Awakn Life Sciences, B.More Inc., and Journey Colab Corp., indicating a competitive landscape despite the 'underserved' claim.
• The company's 2-FDCK compound for depression showed a more prolonged antidepressant effect than ketamine in preclinical models, potentially offering an improvement over existing treatments like FDA-approved esketamine (S-ketamine) for treatment-resistant depression.
• The company's research into 5-MAPB and 6-APB as 'fail-safes' for MDMA therapy suggests an innovative approach to address limitations or resistance in MDMA-assisted psychotherapy, a field where MAPS Public Benefit Corp. recently filed for FDA approval for MDMA in PTSD.

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• **IP Assignment Agreement with Clearmind Labs Corp. (July 28, 2025):** Clearmind Medicine Inc. assigned all rights, title, and interest in certain intellectual property assets, including inventions, discoveries, and patent applications, to its wholly-owned subsidiary, Clearmind Labs Corp. Adi Zuloff Shani, CEO of Clearmind Medicine Inc., also serves as CEO of Clearmind Labs.
• **Cooperation Agreement with SciSparc Ltd. (March 7, 2022):** Clearmind Medicine Inc. and SciSparc Ltd. are exploring scientific and commercial potential for pharmaceutical solutions, including a combined molecule undergoing joint preclinical study. This collaboration has resulted in nine patent filings. If commercial cooperation proceeds, a 50%-50% joint venture will be formed. Adi Zuloff-Shani (Clearmind CEO) is SciSparc's CTO; Amitay Weiss (Clearmind Chairman) is SciSparc's Chairman; Oz Adler (Clearmind Director) is SciSparc's CEO and CFO. Research and development expenses incurred under this agreement were $198,042 in 2025, $50,319 in 2024, and $141,409 in 2023. As of October 31, 2025, SciSparc owed Clearmind $286,488.
• **Research Agreement with Hebrew University of Jerusalem (June 2023):** As part of the SciSparc collaboration, Clearmind entered into this agreement to evaluate a combination treatment for obesity and metabolic syndrome.
• **Compensation to Key Management Personnel:** Compensation includes consulting fees and share-based compensation for officers and directors. For FY2025, officers received $344,802 in consulting fees and $128,254 in share-based compensation. Directors received $358,944 in fees/payroll and $195,101 in share-based compensation. Amounts owed to officers and directors as of October 31, 2025, were $29,761 and $30,471, respectively.
• **Indemnification Agreements:** The company's articles of association allow for indemnification of directors and officers, and the company intends to enter into separate indemnification agreements with them.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk due to ongoing capital raises and warrant exercises. The 'going concern' warning indicates substantial financial risk to their investment. However, positive clinical trial progress and IP expansion offer potential long-term value if successful.
• **Employees:** The company's financial instability and reliance on future funding could create job insecurity. However, the focus on R&D and potential for new drug development offers opportunities for scientific and professional growth.
• **Customers (Future):** If products are approved, they could benefit from novel treatments for underserved mental health and metabolic disorders, potentially improving quality of life. However, market acceptance and reimbursement challenges could limit access.
• **Suppliers/Creditors:** Face credit risk due to the company's accumulated losses and going concern status. The company's ability to meet short-term liabilities depends on securing additional financing.
• **Regulatory Authorities:** The company's activities are subject to extensive regulation by bodies like the FDA and DEA, requiring strict compliance. Positive safety reviews in clinical trials are crucial for continued regulatory support.
• **Research Institutions/Collaborators (e.g., Yissum, BIRAD, SciSparc):** Their intellectual property and research efforts are tied to Clearmind's success. Royalty payments and milestone payments depend on product commercialization. Financial instability at Clearmind could impact future collaboration opportunities or the value of existing agreements.

Next Steps

• Conduct additional clinical trials for CMND-100 for AUD and obesity/metabolic disorder, subject to securing additional financing, following successful completion of Phase I/IIa studies.
• Continue to identify, discover, or license additional product candidates for clinical development.
• Seek regulatory and marketing approvals for any product candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure or enter into collaborations for commercialization of approved products.
• Develop, maintain, protect, and expand the intellectual property portfolio.
• Monitor and comply with evolving controlled substance laws and regulations in target markets.
• Address the 'going concern' issue by securing additional funding through equity or debt financing or strategic collaborations.
• Continue to improve existing and implement new operational and financial systems, procedures, and controls to manage business effectively.

Key Dates

Recommendation

Clearmind Medicine Inc. presents an extremely high-risk investment profile. Despite some positive early-stage clinical data for CMND-100 and an expanding IP portfolio, the company's severe financial distress, evidenced by substantial accumulated losses ($27.88 million), negative cash flow from operations ($4.73 million in FY2025), and an explicit 'going concern' warning from its auditors, indicates a precarious financial position. The continuous need for dilutive capital raises, including multiple offerings and convertible loans in late 2025, highlights an unsustainable burn rate without any product revenue. The early stage of all product candidates means commercialization is years away, with no guarantee of success or profitability. The significant adjustments to warrant exercise prices further underscore the financial pressure and potential for substantial shareholder dilution. Given these fundamental financial weaknesses and the inherent high risks of clinical-stage pharmaceutical development, the probability of significant capital impairment is very high, making it a strong sell for seasoned investors.

Keywords

Psychedelic Medicine, Alcohol Use Disorder, AUD, MEAI, CMND-100, Clinical Trials, Phase I/IIa, Neuroplastogen, Obesity, Metabolic Syndrome, Drug Development, SEC Filing, Biotechnology, Pharmaceutical, Intellectual Property, Going Concern, Capital Raise, Risk Factors, Mental Health